MindMaze Therapeutics Holding SA American Depositary Receipt (RLFTY)
OTC PINK OTC PINK Primary 
XMUN Summary
MindMaze Therapeutics Holding SA American Depositary Receipt (RLFTY) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has MindMaze Therapeutics Holding SA American Depositary Receipt ever had a stock split?
MindMaze Therapeutics Holding SA American Depositary Receipt Profile
| Biotechnology Industry | Healthcare Sector | Zach Henderson CEO | OTC PINK Exchange | 60269B105 CUSIP |
| CH Country | 10 Employees | - Last Dividend | 5 May 2023 Last Split | - IPO Date |
Overview
Relief Therapeutics Holding AG is an international biopharmaceutical company headquartered in Geneva, Switzerland, focusing on the development and delivery of treatments for serious diseases which currently lack adequate therapeutic solutions. The company emphasizes research and development in clinical-stage programs, leveraging molecules with proven clinical use or initial efficacy data backed by strong scientific foundations. It operates across Switzerland, Europe, North America, and globally, aiming to provide therapeutic relief in areas with high unmet medical needs.
Products and Services
- RLF-100 (Aviptadil)
- A Phase 3 trial targeting COVID-19-induced acute respiratory distress syndrome (ARDS) and moderate to severe lung injury directly related to COVID-19.
- A Phase 1 trial focused on the treatment of acute lung injury in patients within the intensive care unit, beyond COVID-19 specifics.
- A Phase 2 trial for the treatment of pulmonary sarcoidosis, indicating the compound's versatility in addressing different respiratory issues.
- ACER-001 (Sodium phenylbutyrate)
- APR-TD011
This lead compound is a synthetic version of the human vasoactive intestinal peptide (VIP), designed for various respiratory conditions. Relief Therapeutics is currently advancing RLF-100 through various clinical trial phases for multiple indications:
A proprietary powder formulation directed at treating urea cycle disorders, this compound represents Relief Therapeutics' approach to metabolic diseases. ACER-001 has successfully completed a Phase 3 clinical trial, underscoring its potential as a viable treatment option. Moreover, it has entered a Phase 1 clinical trial for maple syrup urine disease, expanding its potential therapeutic applications.
As a spray-formulated hypotonic acid-oxidizing solution, APR-TD011 is currently in a Phase 2 clinical trial aimed at treating epidermolysis bullosa, a rare genetic skin disorder. This development highlights Relief Therapeutics' commitment to addressing less common but significantly impactful diseases through innovative therapeutic approaches.
